Transplantation

AbSorber

AbSorber develops products that facilitate successful transplantations.

The company’s first product, XM-ONE®, is CE marked and cleared by the Federal Drug Administration (FDA) in the U.S. The company also develops other products for the transplantation sector, including products that facilitate transplantations between people of different blood groups.

AbSorber was established in 1999 by a group of researchers at the Karolinska University Hospital.

XM -ONE®

Before an organ transplant is executed, a test is performed to ensure that the donor’s tissue will be accepted by the recipient’s immune system. Traditionally this is done by performing a lymphocyte cross-match test that determines if the recipient has antibodies against the donor’s tissue type, so called transplantation Human Leukocyte Antigens (HLA) of class I and/or class II. Despite this control test, a significant number of patients experience immunological complications after the transplantation such as acute rejection episodes and some patients also loses their new kidney within one year of the operation

One reason is that the recipient has antibodies against non-HLA such as endothelial cells (cells that line the inside of the blood vessels) of the transplanted organ. Prior knowledge that a recipient has these antibodies enables the prevention of rejection reactions, either through medication or by selecting an organ from another donor.

AbSorber has developed a standardized test that quickly or antibodies against the donor’s endothelium. XM-ONE® is the first standardized test for detecting antibodies against the endothelium.